HOT NEWS
Pfizer and Medivation Announce Results From Two Phase 3 Studies in Dimebon » Pfizer Inc. (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced results from two Phase 3 trial...
Nycomed on track in 2009 with strong growth in Key Products » Nycomed was on track in 2009, with strong growth in Key Products and most emerging markets. Pantopra...
Bayer Successful in a Difficult Environment » 2009 was operationally one of the strongest years for the Bayer Group. "We were successful in a diff...
Phase III study of Avastin in advanced stomach cancer did not meet primary endpo... » Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the topline results from a global phase III trial inves...
Sanofi Pasteur's A(H1N1) Vaccine HUMENZA®* Recommended by European Medicines Ag... » Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announc...
FY2009: Merck KGaA Revenues Rise by 2.1% to € 7.7 Billion » Merck KGaA announced that Group total revenues rose 2.1% in 2009 - meeting the guidance given earlie...
GSK receives positive opinions in Europe for Tyverb® and Votrient™ » GlaxoSmithKline (GSK) announced that the European Medicines Agency's Committee for Medicinal Product...
My child matters Supports Seven New Childhood Cancer Care Projects » On the International Childhood Cancer Day, the International Union Against Cancer (UICC) and sanofi-...
Abbott Completes Acquisition of Solvay Pharmaceuticals » Abbott (NYSE: ABT) today announced that it has completed its EUR 4.5 billion ($6.2 billion) acquisit...
Merck Receives European Approval for ELONVA® (corifollitropin alfa injection) » Merck & Co., Inc., which operates outside the U.S. and Canada as MSD, today announced the European C...
Novo Nordisk
Novo NordiskNovo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

Novo Nordisk RSS Channel
Filter     Display # 
# Article Title Hits
1 Danish companies join forces to compete for global talent 382
2 Novo Nordisk starts phase 1 trial with long-acting oral GLP-1 analogue 475
3 Novo Nordisk and Combine in research collaboration for the treatment of autoimmune diseases 471
4 EFSD/Novo Nordisk partnership for diabetes research in Europe 776
5 Novo Nordisk increased operating profit by 30% in the first nine months of 2009 440
6 The Lancet publishes direct comparison study between liraglutide and exenatide 990
7 Novo Nordisk and VLST Corporation announce collaboration agreement 529
8 Urgent need for social and psychological support for young people with diabetes 767
9 Novo Nordisk acquires intellectual property rights from Neose Technologies 533
 
Bookmark and Share

Banner